KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Non Operating Investment Income (2016 - 2017)

Historic Non Operating Investment Income for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Q2 2017 value amounting to $23000.0.

  • Supernus Pharmaceuticals' Non Operating Investment Income fell 8130.08% to $23000.0 in Q2 2017 from the same period last year, while for Dec 2017 it was $77000.0, marking a year-over-year decrease of 8281.25%. This contributed to the annual value of $76000.0 for FY2017, which is 8303.57% down from last year.
  • Supernus Pharmaceuticals' Non Operating Investment Income amounted to $23000.0 in Q2 2017, which was down 8130.08% from $54000.0 recorded in Q1 2017.
  • In the past 5 years, Supernus Pharmaceuticals' Non Operating Investment Income ranged from a high of $760000.0 in Q3 2014 and a low of -$8.6 million during Q2 2013
  • Moreover, its 5-year median value for Non Operating Investment Income was $100000.0 (2016), whereas its average is -$545944.4.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Non Operating Investment Income crashed by 588541.67% in 2013 and then surged by 1220000.0% in 2016.
  • Over the past 5 years, Supernus Pharmaceuticals' Non Operating Investment Income (Quarter) stood at -$662000.0 in 2013, then soared by 204.83% to $694000.0 in 2014, then tumbled by 81.7% to $127000.0 in 2015, then dropped by 22.05% to $99000.0 in 2016, then tumbled by 76.77% to $23000.0 in 2017.
  • Its Non Operating Investment Income stands at $23000.0 for Q2 2017, versus $54000.0 for Q1 2017 and $99000.0 for Q4 2016.